Royalty Pharma Plc
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 20 development-stage product candidates that address various therapeutic areas, such as rare disease, oncology, neuroscience, infectious disease, hematology, and diabe… Read more
Royalty Pharma Plc (RPRX) - Total Liabilities
Latest total liabilities as of December 2025: $9.91 Billion USD
Based on the latest financial reports, Royalty Pharma Plc (RPRX) has total liabilities worth $9.91 Billion USD as of December 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Royalty Pharma Plc - Total Liabilities Trend (2000–2025)
This chart illustrates how Royalty Pharma Plc's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Royalty Pharma Plc Competitors by Total Liabilities
The table below lists competitors of Royalty Pharma Plc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Charter Communications Inc
NASDAQ:CHTR
|
USA | $133.69 Billion |
|
Aviva plc
PINK:AIVAF
|
USA | $353.67 Billion |
|
Henkel AG & Co. KGaA vz. (Pref Shares)
XETRA:HEN3
|
Germany | €12.67 Billion |
|
Hannover Rück SE
PINK:HVRRF
|
USA | $57.45 Billion |
|
Northern Star Resources Limited
F:NS7
|
Germany | €5.52 Billion |
|
Vodafone Group PLC
PINK:VODPF
|
USA | $72.25 Billion |
|
Credicorp Ltd
NYSE:BAP
|
USA | $230.00 Billion |
|
Southwest Airlines Company
NYSE:LUV
|
USA | $21.08 Billion |
Liability Composition Analysis (2000–2025)
This chart breaks down Royalty Pharma Plc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.97 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.53 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.50 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Royalty Pharma Plc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Royalty Pharma Plc (2000–2025)
The table below shows the annual total liabilities of Royalty Pharma Plc from 2000 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $9.91 Billion | +25.70% |
| 2024-12-31 | $7.88 Billion | +25.13% |
| 2023-12-31 | $6.30 Billion | -13.59% |
| 2022-12-31 | $7.29 Billion | +0.29% |
| 2021-12-31 | $7.27 Billion | +18.67% |
| 2020-12-31 | $6.12 Billion | -2.92% |
| 2019-12-31 | $6.31 Billion | -7.47% |
| 2018-12-31 | $6.82 Billion | -1.25% |
| 2017-12-31 | $6.90 Billion | +14.65% |
| 2016-12-31 | $6.02 Billion | -1.58% |
| 2015-12-31 | $6.12 Billion | +209153.76% |
| 2014-12-31 | $2.92 Million | -17.68% |
| 2013-12-31 | $3.55 Million | -6.48% |
| 2012-12-31 | $3.80 Million | +171.67% |
| 2011-12-31 | $1.40 Million | +7.70% |
| 2010-12-31 | $1.30 Million | -45.87% |
| 2009-12-31 | $2.40 Million | -65.69% |
| 2008-12-31 | $6.99 Million | +97.49% |
| 2007-12-31 | $3.54 Million | -12.81% |
| 2006-12-31 | $4.06 Million | +458.32% |
| 2005-12-31 | $727.00K | +18.40% |
| 2004-12-31 | $614.00K | +13.49% |
| 2003-12-31 | $541.00K | +4.24% |
| 2002-12-31 | $519.00K | -91.82% |
| 2001-12-31 | $6.34 Million | -31.88% |
| 2000-12-31 | $9.31 Million | -- |